Armed with a comprehensive understanding of life science real estate ecology and proactive strategic planning, Dino Perazzo is a recognized real estate authority and advocate within the life science community. He leads CBRE’s Bay Area life science practice, and has used his relational network and market knowledge to develop a full-spectrum, strategic real estate approach that is both qualified and reflective of the state of the life science industry.
Dino advises clients both in local and global markets. His breadth of knowledge of the intricacies behind the roles and responsibilities within the drug development paradigm makes Dino instrumental in life science portfolio consulting. Collectively, this expertise empowers his clients to effectively mitigate risk while leveraging all real estate opportunities in this evolving life science market.
Dino has been involved in over $5 billion in sales activity and over 10 million square feet of leasing transactions. Dino has consistently been ranked as a top professional in San Francisco and as the number one professional in each of the past 15 years. In addition, he has been ranked in the company’s elite producers regularly, representing the top 3% of professionals worldwide.
Education
- San Diego State University; Bachelors of Science, Business Administration
Pro Affiliations / Accreditations
- Executive Council: CBRE Life Science Practice
- Member: California Life Sciences
- CCIM
Achievements
- CBRE Top Producer: National
- CBRE Number One Producer: San Francisco
- Rookie of the Year
- 40 Under 40 Most Influential Leaders – San Francisco Business Times Awards
Clients Represented (Partial List)
- AbbVie
- Aerovance
- Biomed Realty
- Codexis
- DuPont/Pioneer Hi-Bred
- Elan Pharmaceuticals
- Five Prime Therapeutics
- Geron
- Grifols
- Healthpeak Properties
- Hyperion Therapeutics
- KKR
- Lilly
- Longfellow Real Estate Partners
- MacroGenics
- Mereo BioPharma
- Millennium Pharmaceuticals
- Roche
- Rubicor Medical
- Sunesis Pharmaceuticals
- Takeda Pharmaceuticals
- Tercica
- Titan Pharmaceuticals
- Ventas
- Xenoport
